What ORCID Is and Why Persistent Identifiers Matter
An ORCID iD distinguishes a research contributor from similar names and connects that person to works and affiliations through traceable metadata.
Health & Evidence Library
Essays on scientific thinking, uncertainty, communication, ethics, narrative, and the human work of medicine.
41 guides · Page 1 of 1
An ORCID iD distinguishes a research contributor from similar names and connects that person to works and affiliations through traceable metadata.
Why this growing educational library exists, how its sources are selected, and how Jasaman Tojjar reviews every case analysis and evidence guide.
No. This site is an educational evidence library or diagnosis. Learn what it is, who is responsible, and when to see a clinician.
The U.S. Public Health Service syphilis study used deception and withheld treatment. Its disclosure accelerated federal research protections.
Cluster studies reveal heterogeneity within adult-onset diabetes, but proposed subtypes are not yet routine diagnostic categories or treatment rules.
Moving from discovery to routine benefit requires linked evidence about mechanisms, trials, implementation, access, and population outcomes.
The 1947 Nuremberg Code made voluntary consent foundational to research ethics, while later frameworks built protections beyond a signed form.
Diagnostic language can transmit evidence, uncertainty, respect, or bias. Better wording is accurate, contextual, preference-aware, and useful for care.
Why repeating a study requires more than copying a methods section and how stronger replication designs clarify what a result means.
Why trustworthy methods, institutions, communication, accountability, and public participation matter more than demands to trust science.
A discovery must survive validation, engineering, funding, regulation, clinical testing, manufacturing, and implementation before it can improve care.
Why corrected claims can still shape memory and reasoning, and how fact-first corrections with a coherent alternative explanation can work better.
How ethics, history, narrative, language, and the arts sharpen observation, judgment, communication, and reflection without replacing science.
Evidence-based medicine grew from fair treatment comparisons, clinical epidemiology, systematic reviews, critical appraisal, and shared decisions.
The 1948 MRC streptomycin study became a landmark because random allocation, concealment, concurrent controls, and blinded assessment worked together.
Medical decisions rarely come with certainty. Ethical care makes uncertainty explicit, quantifies it when possible, and builds a plan around it.
How screening, prediction, risk tiers, and treatment-effect evidence can make type 2 diabetes prevention more precise and equitable.
A framework for precision diabetes medicine across diagnosis, prevention, treatment, and prognosis, including utility, fairness, and evidence gaps.
Autonomy, beneficence, non-maleficence, and justice explained through everyday care, competing duties, and a practical reasoning process.
RECOVERY produced rapid randomized answers through a master protocol, concurrent controls, simple enrollment, large scale, and prespecified analyses.
The insulin breakthrough as a chain of prior science, teamwork, purification, patient evidence, manufacturing, revision, and unfinished access.
A regulator-grounded map from biological hypothesis and product design through preclinical work, human trials, review, manufacturing, and implementation.
Insulin sensitivity and insulin secretion vary across populations, so a single global cutoff can both miss and mislabel diabetes risk.
A plain-language tour of how a medicine moves through worldwide clinical programs, and why doing it well takes years.
A neutral explainer of the FDA's 2026 revised draft guidance on master protocols and the tradeoffs of shared controls and multiplicity.
How the WMA Declaration of Helsinki governs human research and what its October 2024 revision changed for consent, biobanks, and emergencies.
The 1979 Belmont Report distilled human-research ethics into three principles that still shape how every ethics board judges a study.
A plain-language look at what coronary polygenic risk scores measure, the modest accuracy they add, and why they transfer poorly across ancestries.
What narrative medicine is, why a patient's story sharpens care, and how stories and evidence work together rather than against each other.
Why MODY gets mistaken for type 1 or type 2 diabetes, the clues that should trigger genetic testing, and how the right gene changes treatment.
How the HeLa story and the 2013 NIH-Lacks family agreement turned informed consent from a one-time signature into ongoing governance of genomic data.
What gestational diabetes is, why pregnancy raises blood sugar, and what the diagnosis does and does not mean for the years ahead.
How a diabetes discovery becomes a treatment, the stages of translational medicine, and why most promising findings never finish the journey.
How a pretreatment DPYD gene test cuts the risk of severe 5-FU and capecitabine toxicity, what CPIC advises, and what a normal result cannot promise.
Modern type 2 diabetes care aims at the heart and kidneys themselves, not at the glucose number alone. Here is why the goal changed.
How CYP2C19 genotype blunts clopidogrel, what the FDA boxed warning and the 2022 CPIC guideline say, and where the outcome evidence is strong or thin.
What the Jefferson Scale of Empathy really measures, why psychometricians trust it, and where the outcome evidence stops short.
What good mentorship in medicine looks like, why it matters for both mentor and learner, and how to make it more than an accident.
Practical habits for keeping up with medical evidence without drowning in it, and why staying current is a skill rather than a burden.
How research across whole populations connects to the care of one individual, and why a population view makes everyday medicine better.
What research training contributes to question framing, evidence appraisal, and honest decisions under uncertainty in health care.